Treasury & Bonds
View Full List
Dow Jones Industrial Average
Standard & Poors 500
NYSE COMPOSITE INDX
Drug Manufacturers - Other Sector
Streaming Delayed Price
2:52 PM EDT, Jun 26, 2017
Add to My Watchlist
Price and Volume
1621.45 - 1645.57
1353.74 - 1982.48
NORDISK SP ADR-B
SHIRE SP ADR
TEVAPHARMIND SP ADR
DR REDDY'S LB SPADR
UNITED THERAPEUT RG
OPKO HEALTH RG
AMARIN SP ADR
Wall Street really doesn’t want you to sell stocks
Today 13:48 EDT
Not a single S&P 500 stock has majority ‘sell’ ratings from analysts.
Uptrend Call Working As Vertex Pharm Stock Rises 68.8% (VRTX)
Today 13:36 EDT
SmarTrend identified an Uptrend for Vertex Pharm (NASDAQ:VRTX) on January 6th, 2017 at $78.63. In approximately 6 months, Vertex Pharm has returned 68.76% as of today's recent price of...
Comtex SmarTrend® News Briefs
3 Cheap Healthcare Stocks You Can Buy Right Now
Today 13:08 EDT
645% Growth May Push This Biotech Stock Into New Buy Zone
Today 11:36 EDT
A Relative Strength Rating upgrade for Innoviva shows improving technical performance. Will it continue?
Investor's Business Daily
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating ArQule, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Today 11:22 EDT
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of...
Attention To Details: Neos' ADHD Portfolio
Today 9:05 EDT
Neos Therapeutics Inc (NASDAQ: NEOS) shares began tumbling on June 21, despite announcing late on June 20 that the FDA approved its ...
Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
Today 9:00 EDT
Today, Korea Investment Partners (KIP), DSC Investments, Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases...
Business Wire News Releases
BRIEF-Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer
Today 8:42 EDT
* Xenetic Biosciences commences patient enrollment in phase 2 study evaluating XBIO-101 in conjunction with Progestin therapy for the treatment of endometrial cancer
Reuters: Company News
Stock Market JSON API
provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Terms and Conditions
Press Release Service
provided by PRConnect.
Stock quotes supplied by Six Financial